204 related articles for article (PubMed ID: 25595894)
21. miR-199a-5p suppresses epithelial- mesenchymal-transition in anaplastic thyroid carcinoma cells via targeting Snail signals.
Hao F; Bi YN; Wang L; Wang Y; Ma J; Cui P; Li X; Sun S; Ning L; Huang Y; Jiao X; Chen D
Cancer Biomark; 2020; 29(3):317-326. PubMed ID: 32716347
[TBL] [Abstract][Full Text] [Related]
22. Tumor suppressor role of the CL2/DRO1/CCDC80 gene in thyroid carcinogenesis.
Ferraro A; Schepis F; Leone V; Federico A; Borbone E; Pallante P; Berlingieri MT; Chiappetta G; Monaco M; Palmieri D; Chiariotti L; Santoro M; Fusco A
J Clin Endocrinol Metab; 2013 Jul; 98(7):2834-43. PubMed ID: 23666966
[TBL] [Abstract][Full Text] [Related]
23. Krüppel-like factor 4, a tumor suppressor in hepatocellular carcinoma cells reverts epithelial mesenchymal transition by suppressing slug expression.
Lin ZS; Chu HC; Yen YC; Lewis BC; Chen YW
PLoS One; 2012; 7(8):e43593. PubMed ID: 22937066
[TBL] [Abstract][Full Text] [Related]
24. Downregulation of CSN6 attenuates papillary thyroid carcinoma progression by reducing Wnt/β-catenin signaling and sensitizes cancer cells to FH535 therapy.
Wen D; Liao T; Ma B; Qu N; Shi RL; Lu ZW; Wang YL; Wei WJ; Ji QH
Cancer Med; 2018 Feb; 7(2):285-296. PubMed ID: 29341469
[TBL] [Abstract][Full Text] [Related]
25. TWIST1/miR-584/TUSC2 pathway induces resistance to apoptosis in thyroid cancer cells.
Orlandella FM; Di Maro G; Ugolini C; Basolo F; Salvatore G
Oncotarget; 2016 Oct; 7(43):70575-70588. PubMed ID: 27661106
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA 483-3p targets Pard3 to potentiate TGF-β1-induced cell migration, invasion, and epithelial-mesenchymal transition in anaplastic thyroid cancer cells.
Zhang X; Liu L; Deng X; Li D; Cai H; Ma Y; Jia C; Wu B; Fan Y; Lv Z
Oncogene; 2019 Jan; 38(5):699-715. PubMed ID: 30171257
[TBL] [Abstract][Full Text] [Related]
27. Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells.
Chen H; Luo D; Zhang L; Lin X; Luo Q; Yi H; Wang J; Yan X; Li B; Chen Y; Liu X; Zhang H; Liu S; Qiu M; Yang D; Jiang N
Oncotarget; 2017 Jun; 8(26):43008-43022. PubMed ID: 28498808
[TBL] [Abstract][Full Text] [Related]
28. 5'-AMP-Activated Protein Kinase Regulates Papillary (TPC-1 and BCPAP) Thyroid Cancer Cell Survival, Migration, Invasion, and Epithelial-to-Mesenchymal Transition.
Cazarin JM; Coelho RG; Hecht F; Andrade BM; Carvalho DP
Thyroid; 2016 Jul; 26(7):933-42. PubMed ID: 27121619
[TBL] [Abstract][Full Text] [Related]
29.
Vosgha H; Ariana A; Smith RA; Lam AK
Endocr Relat Cancer; 2018 Mar; 25(3):323-337. PubMed ID: 29317480
[TBL] [Abstract][Full Text] [Related]
30. Loss of One or Two PATZ1 Alleles Has a Critical Role in the Progression of Thyroid Carcinomas Induced by the RET/PTC1 Oncogene.
Monaco M; Palma G; Vitiello M; Capiluongo A; D'Andrea B; Vuttariello E; Luciano A; Cerchia L; Chiappetta G; Arra C; Fusco A; Fedele M
Cancers (Basel); 2018 Mar; 10(4):. PubMed ID: 29584698
[TBL] [Abstract][Full Text] [Related]
31. hRAD9 functions as a tumor suppressor by inducing p21-dependent senescence and suppressing epithelial-mesenchymal transition through inhibition of Slug transcription.
Wen FC; Chang TW; Tseng YL; Lee JC; Chang MC
Carcinogenesis; 2014 Jul; 35(7):1481-90. PubMed ID: 24403312
[TBL] [Abstract][Full Text] [Related]
32. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.
Nikitski AV; Rominski SL; Condello V; Kaya C; Wankhede M; Panebianco F; Yang H; Altschuler DL; Nikiforov YE
Thyroid; 2019 Oct; 29(10):1425-1437. PubMed ID: 31298630
[No Abstract] [Full Text] [Related]
33. Tanshinone IIA inhibits viral oncogene expression leading to apoptosis and inhibition of cervical cancer.
Munagala R; Aqil F; Jeyabalan J; Gupta RC
Cancer Lett; 2015 Jan; 356(2 Pt B):536-46. PubMed ID: 25304375
[TBL] [Abstract][Full Text] [Related]
34. Concurrent overexpression of RET/PTC1 and TTF1 confers tumorigenicity to thyrocytes.
Endo T; Kobayashi T
Endocr Relat Cancer; 2013 Dec; 20(6):767-76. PubMed ID: 24014739
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-137 represses FBI-1 to inhibit proliferation and in vitro invasion and migration of hepatocellular carcinoma cells.
Zhu M; Li M; Wang T; Linghu E; Wu B
Tumour Biol; 2016 Oct; 37(10):13995-14008. PubMed ID: 27492460
[TBL] [Abstract][Full Text] [Related]
36. MiR-20b Displays Tumor-Suppressor Functions in Papillary Thyroid Carcinoma by Regulating the MAPK/ERK Signaling Pathway.
Hong S; Yu S; Li J; Yin Y; Liu Y; Zhang Q; Guan H; Li Y; Xiao H
Thyroid; 2016 Dec; 26(12):1733-1743. PubMed ID: 27717302
[TBL] [Abstract][Full Text] [Related]
37. Down-regulation of SOSTDC1 promotes thyroid cancer cell proliferation via regulating cyclin A2 and cyclin E2.
Liang W; Guan H; He X; Ke W; Xu L; Liu L; Xiao H; Li Y
Oncotarget; 2015 Oct; 6(31):31780-91. PubMed ID: 26378658
[TBL] [Abstract][Full Text] [Related]
38. Interactions of Vascular Endothelial Growth Factor and p53 with miR-195 in Thyroid Carcinoma: Possible Therapeutic Targets in Aggressive Thyroid Cancers.
Maroof H; Irani S; Arianna A; Vider J; Gopalan V; Lam AK
Curr Cancer Drug Targets; 2019; 19(7):561-570. PubMed ID: 29956628
[TBL] [Abstract][Full Text] [Related]
39. Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors.
Antico Arciuch VG; Russo MA; Dima M; Kang KS; Dasrath F; Liao XH; Refetoff S; Montagna C; Di Cristofano A
Oncotarget; 2011 Dec; 2(12):1109-26. PubMed ID: 22190384
[TBL] [Abstract][Full Text] [Related]
40. Shikonin inhibits thyroid cancer cell growth and invasiveness through targeting major signaling pathways.
Yang Q; Ji M; Guan H; Shi B; Hou P
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1909-17. PubMed ID: 24106286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
